Tina K. Sacks, PhD, Katie Savin, MSW, and Quenette L. Walton, PhD, LCSW
Would you question health decisions made by a 37-year old Black woman whose great-grandfather died in the US Public Health Service Syphilis Study at Tuskegee?
AMA J Ethics. 2021;23(2):E183-188. doi:
10.1001/amajethics.2021.183.
Jesse Feierabend-Peters, MD, PhD and Hugh Silk, MD, MPH
Despite availability of good national oral health curricula for medical trainees, most physicians are ill-equipped to identify oral cancers or avoid unnecessary referrals.
AMA J Ethics. 2022;24(1):E19-26. doi:
10.1001/amajethics.2022.19.
Mary Anderlik Majumder, JD, PhD and Christi J. Guerrini, JD
Amendments to the Common Rule and Health Insurance Portability and Accountability Act (HIPAA) raise questions about broad consent and sale of health data.
AMA J Ethics. 2016;18(3):288-298. doi:
10.1001/journalofethics.2016.18.3.pfor5-1603.
Financial relationships are common, and ethical questions rightly emerge about how conflicts of interest compromise investigators’ approaches to research.
AMA J Ethics. 2021;23(9):E685-691. doi:
10.1001/amajethics.2021.685.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"